Table 1 Patient and treatment characteristics
Patient and treatment characteristics (n = 60) | |
|---|---|
Midian age (years) | 53 (29–84) |
≥ 50 years | 40 (67%) |
<50 years | 20 (33%) |
Histology | |
Squamous cell | 56 (93%) |
Adenocarcinoma | 4 (7%) |
Pre-treatment MRI-based maximal diameter (mm) | 43 (10–82) |
>40 mm | 35 (58%) |
≤40 mm | 25 (42%) |
Pre-treatment SCC lever (ng/ml) | 17.7 (0.4–70) |
Chemotherapy | |
Yes | 50 (83%) |
Cycles | 4 (1–6) |
Regimen | Cisplatin Nedaplatin Platin-based doublet therapy |
No | 10 (17%) |
Initial treatment | |
Neoadjuvant chemotherapy + CCRT/RT | 31 (52%) |
CCRT | 14 (23%) |
Radiotherapy alone | 10 (17%) |
CCRT/RT + adjuvant chemotherapy | 5 (8%) |
RT dose (Gy) | |
EBRT to pelvis with or without abdomen | 45 (45–50) |
Brachytherapy to primary lesion (EQD2) | 40 (32–70) |
EBRT boost to gross node disease | 10 (8–14) |
EBRT to distant LN | 60 (60–74) |
EBRT to metastatic organ | 60 (60–70) |
Metastatic Sites at Diagnosis | |
Supraclavicular lymph node | 45 |
Inguinal lymph node | 16 |
Axillary lymph node | 4 |
Mediastinal lymph node | 1 |
Lung Parenchymal metastases | 3 |
Bony metastases in pelvis | 3 |
Extrapelvic bony metastases | 4 |
Other (adrenal gland, gluteus maximus) | 2 |
Number of Metastatic sites at Diagnosis | |
1 | 43 (72%) |
2 | 14 (23%) |
3 | 2 (3%) |
4 | 1(2%) |